Phase 1a Study in Healthy Smokers to Investigate the Effect With MMI-0100 on Airway Inflammation in Induced Sputum After Challenge With Inhaled Lipopolysaccharide

NCT02515396 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Inflammatory Response to Non-antigenic Stimulus

Interventions

DRUG: MMI-0100
DRUG: Placebo

Sponsor

Moerae Matrix, Inc.